ANRO supply chain intelligence for Alto Neuroscience, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Alto Neuroscience, Inc. (ANRO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BOFA-SECURITIES-INC | BOFA-SECURITIES-INC | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| CERECOR-INC | CERECOR-INC | 90% | we obtained an exclusive worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights and know-how owned or controlled by Cerecor |
| JEFFERIES-LLC | JEFFERIES-LLC | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| MEDRX-CO-LTD | MEDRX-CO-LTD | 90% | we obtained an exclusive, sublicensable, worldwide license, with the right to sublicense, under certain patent rights and know-how of MedRx |
| PALISADE-BIO-INC | PALISADE-BIO-INC | 90% | we acquired all patent, know-how and other rights to ALTO-100 |
| ROBERT-W-BAIRD-CO-INCORPORATED | ROBERT-W-BAIRD-CO-INCORPORATED | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| STIFEL-NICOLAUS-COMPANY-INCORPORATED | STIFEL-NICOLAUS-COMPANY-INCORPORATED | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | 90% | we acquired patents, know-how and other rights to ALTO-203 and a specified related compound, or Teva Acquired Compounds |
| WILLIAM-BLAIR-COMPANY-L-L-C | WILLIAM-BLAIR-COMPANY-L-L-C | 90% | The Company has engaged Jefferies LLC, BofA Securities, Inc., TD Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C. and Robert W. Baird & Co. Incorporated… |
| DOW-AGROSCIENCES-LLC | DOW-AGROSCIENCES-LLC | 80% | we licensed patent rights covering an intermediate compound in the manufacturing process for ALTO-100 |
| HTCO | High-Trend International Group | 72% | Reciprocal relationship from HTCO graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from HTCO graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from HTCO g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | 72% | Reciprocal relationship from AVTX graph: Reciprocal relationship from ANRO graph: ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rig… |
| AVTX | Avalo Therapeutics, Inc. | 72% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| PALI | Palisade Bio, Inc. | 72% | Reciprocal relationship from PALI graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from PALI graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from PALI g… |
| PALI | Palisade Bio, Inc. | 72% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| SNYNF | Sanofi | 72% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ANRO graph: ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property ri… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from XENE graph: Reciprocal relationship from ANRO graph: Reciprocal relationship from XENE g… |
| ANKURA-TRUST-COMPANY-LLC | ANKURA-TRUST-COMPANY-LLC | 62% | ral and Administrative Expenses General and administrative expenses were $6.8 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025. Th… |
| CAPITAL-RESOURCES | CAPITAL-RESOURCES | 62% | ellectual property portfolio; • seek to attract and retain new and existing skilled personnel; and • add operational, legal, financial and management information systems and personnel to support our … |
| DOW-AGROSCIENCES-LLC | DOW-AGROSCIENCES-LLC | 62% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| ESSEX-CHEMIE-AG | ESSEX-CHEMIE-AG | 62% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| K2-HEALTHVENTURES-LLC | K2-HEALTHVENTURES-LLC | 62% | ral and Administrative Expenses General and administrative expenses were $6.8 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025. Th… |
| LEERINK-PARTNERS-LLC | LEERINK-PARTNERS-LLC | 62% | ral and Administrative Expenses General and administrative expenses were $6.8 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025. Th… |
| LENDERS-K2-HEALTHVENTURES-LLC | LENDERS-K2-HEALTHVENTURES-LLC | 62% | ral and Administrative Expenses General and administrative expenses were $6.8 million for the three months ended March 31, 2026, compared to $5.7 million for the three months ended March 31, 2025. Th… |
| TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | TEVA-PHARMACEUTICAL-INDUSTRIES-LTD | 62% | ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims; • the terms and timing of… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ANRO-DEBT-7771 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| ANRO-DEBT-7770 | Warrants outstanding: 524000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| ANRO-DEBT | Debt stack $16.2M | 90% | Market cache reports total debt of $16.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ANRO-OWNER-PERCEPTIVE-ADVISORS-LLC | PERCEPTIVE ADVISORS LLC | 90% | 13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 112 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| GRDX | GridAI Technologies Corp. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 |